- Home
- NIVF vs NDRA Comparison
NIVF vs NDRA Comparison
Compare NIVF & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- NDRA
- Stock Information
- Founded
- NIVF 2011
- NDRA 2007
- Country
- NIVF Thailand
- NDRA United States
- Employees
- NIVF N/A
- NDRA N/A
- Industry
- NIVF
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NIVF
- NDRA Health Care
- Exchange
- NIVF NYSE
- NDRA Nasdaq
- Market Cap
- NIVF 2.1M
- NDRA 2.3M
- IPO Year
- NIVF N/A
- NDRA 2017
- Fundamental
- Price
- NIVF $2.20
- NDRA $3.36
- Analyst Decision
- NIVF
- NDRA Strong Buy
- Analyst Count
- NIVF 0
- NDRA 1
- Target Price
- NIVF N/A
- NDRA $46.00
- AVG Volume (30 Days)
- NIVF 7.7M
- NDRA 97.6K
- Earning Date
- NIVF 01-01-0001
- NDRA 05-15-2025
- Dividend Yield
- NIVF N/A
- NDRA N/A
- EPS Growth
- NIVF N/A
- NDRA N/A
- EPS
- NIVF N/A
- NDRA N/A
- Revenue
- NIVF $5,433,375.00
- NDRA N/A
- Revenue This Year
- NIVF N/A
- NDRA N/A
- Revenue Next Year
- NIVF N/A
- NDRA N/A
- P/E Ratio
- NIVF N/A
- NDRA N/A
- Revenue Growth
- NIVF 5.79
- NDRA N/A
- 52 Week Low
- NIVF $1.68
- NDRA $2.90
- 52 Week High
- NIVF $656.00
- NDRA $286.48
- Technical
- Relative Strength Index (RSI)
- NIVF 41.58
- NDRA 44.40
- Support Level
- NIVF $1.68
- NDRA $3.31
- Resistance Level
- NIVF $6.13
- NDRA $3.80
- Average True Range (ATR)
- NIVF 0.74
- NDRA 0.26
- MACD
- NIVF 0.10
- NDRA 0.04
- Stochastic Oscillator
- NIVF 11.69
- NDRA 50.28
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.